comparemela.com

Latest Breaking News On - Nasdaq cgem - Page 4 : comparemela.com

Cullinan Oncology to Present New Preclinical Data for

CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with advanced solid tumors. Initial.

United statesUnited kingdomPatrick baeuerleJennifers michaelsonK dane wittrupKerrya whalenPatricka baeuerleRose weldonKristan meetzeNaveenk mehtaKavya rakhraExchange commissionAmerican association for cancer researchCullinan oncology incInvestigational new drug applicationCancer research

Cullinan Oncology Licenses U S Rights to the First

CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan.

United kingdomJingsong wangNadim ahmedExchange commissionCullinan oncology incHarbour biomedCullinan oncologyChief executive officerPrivate securities litigation reform actAnnual reportNasdaq cgemCullinan oncology inc

Cullinan Oncology Reports Inducement Grants Under Nasdaq

CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on.

United kingdomCompany board of directorsCullinan oncology incCullinan oncologyNasdaq listing ruleNasdaq cgemCullinan oncology inc

Cullinan Oncology Reports Inducement Grants Under Nasdaq

CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on.

United kingdomCompany board of directorsCullinan oncology incCullinan oncologyNasdaq listing ruleNasdaq cgemCullinan management

Cullinan Oncology Reports Inducement Grants Under Nasdaq

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on.

United kingdomCompany board of directorsCullinan oncology incCullinan oncologyNasdaq listing ruleNasdaq cgemCullinan management

vimarsana © 2020. All Rights Reserved.